BridgeBio Pharma (BBIO) Price/FCF Ratio: History & Chart

BridgeBio Pharma, Inc.(BBIO)

Biotechnology · Palo Alto, CA

$66.14-1.11 (-1.65%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.

Palo Alto, CA

999 employees

www.bridgebio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Neil Kumar

View full financials

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
BridgeBio Pharma, Inc. (BBIO)	$12.95B	N/A	N/A	N/A	N/A
ICON Public Limited Company (ICLR)vs ›	$12.89B	9.57	10.84	18.62	24.18
Corcept Therapeutics Incorporated (CORT)vs ›	$13.19B	123.37	63.68	44.61	34.61
Baxter International Inc. (BAX)vs ›	$12.52B	18.47	27.97	30.18	29.47
Penumbra, Inc. (PEN)vs ›	$12.49B	57.85	69.09	523.51	1612.31
BrightSpring Health Services, Inc. Common Stock (BTSG)vs ›	$12.17B	30.24	30.61	87.87	87.87
Encompass Health Corporation (EHC)vs ›	$12.00B	29.03	26.04	31.84	34.91
Ascendis Pharma A/S (ASND)vs ›	$14.16B	36.61	241.04	241.04	241.04
DaVita Inc. (DVA)vs ›	$11.47B	7.13	8.47	8.85	8.53
Bio-Techne Corporation (TECH)vs ›	$11.36B	43.17	39.77	43.43	47.32

NAME

MARKET CAP

PRICE/FCF RATIO

TTM

BridgeBio Pharma, Inc. (BBIO)

$12.95B

N/A

ICON Public Limited Company (ICLR)vs ›

$12.89B

9.57

10.84

18.62

24.18

Corcept Therapeutics Incorporated (CORT)vs ›

$13.19B

123.37

63.68

44.61

34.61

Baxter International Inc. (BAX)vs ›

$12.52B

18.47

27.97

30.18

29.47

Penumbra, Inc. (PEN)vs ›

$12.49B

57.85

69.09

523.51

1612.31

BrightSpring Health Services, Inc. Common Stock (BTSG)vs ›

$12.17B

30.24

30.61

87.87

Encompass Health Corporation (EHC)vs ›

$12.00B

29.03

26.04

31.84

34.91

Ascendis Pharma A/S (ASND)vs ›

$14.16B

36.61

241.04

DaVita Inc. (DVA)vs ›

$11.47B

7.13

8.47

8.85

8.53

Bio-Techne Corporation (TECH)vs ›

$11.36B

43.17

39.77

43.43

47.32

Price/FCF Ratio: N/A

BBIO Price/FCF Ratio Metrics

BBIO Competitors' Price/FCF Ratio

Free Cash Flow Valuation

Price/FCF Ratio Formula & Definition

Related Metrics